Opyl Ltd (OPL)

Announcements

Company Overview

Dividend History

DPS and Yield calculations use the Pay Date.

Directors & Management

Name	Title	Since	Bio
Dr Megan Robertson	Non-Executive Director	May 2021	Dr Megan Robertson Non-Executive Director Dr Robertson has clinical and commercial experience and knowledge in the health sector. She is the current Group Chief Research Officer at St Vincent's Health Australia and Director of Research at St Vincent's Hospital, Melbourne. She also works as a Senior Intensive Care Consultant at Epworth HealthCare (Richmond and Freemasons). She is on the boards of the Digital Health CRC, St Vincent's Institute of Medical Research, FearLess (PTSD-ANZ), and Queen's College (Univ of Melbourne), and the Tuckwell Scholarship Selection Panel at ANU. She also works with national bodies including the Australian Commission on Safety and Quality in Healthcare, AusBiotech, and the National Health and Medical Research Council. Previously, she held positions as the Director of Professional Affairs, CICM, as the Executive Director of Research at Epworth HealthCare, and as the Co-Director of the Intensive Care Unit at Epworth Freemasons. She has led initiatives in the St Vincent's Research Directorate including the establishment of the St Vincent's Research Valet Service, development of the Victorian Clinical Trial Gateway portal, Clinical Trials Business Development model, facilitated research activities of the Research Governance Unit, and built linkages between clinicians/researchers and industry, as well as linkages between clinicians/researchers and community.
Mr Mark Ziirsen	Non-Executive Director	Sep 2020	Mr Mark Ziirsen Non-Executive Director Mr Ziirsen is an experienced ASX listed, non-executive director and CFO. He served as non-executive director and chair of Respiri Limited, an eHealth SaaS company supporting respiratory health management, and as non-executive director and chair of the Audit and Risk Committee of Orcoda Limited, a SaaS-based technology company. His executive career includes senior finance leadership roles with ASX listed companies including Cochlear Limited, Aristocrat Leisure Limited, Coca-Cola Amatil Limited and Goodman Fielder Limited. He commenced his career with EY in business advisory, tax and management consulting. Most recently, he was CFO and company secretary for Wiseway Group Limited where he led the company through an IPO, listing on ASX. Immediately prior to that he was CFO of listed medtech company Anteris Technologies Limited and before that, Director of Finance and IT for Asia Pacific at hearing implant maker Cochlear Limited. Mark has experience across multiple industry sectors (medtech/health, technology, consumer) and geographies, having worked in Asia for more than 25 years. He is also appointed chair of the Risk committee of the company.
Mr David Lilja	Company Secretary	Dec 2019
Dr Julian John Chick	Non-Executive Director	May 2019	Dr Julian John Chick Non-Executive Director Dr Chick is an executive with more than 25 years of experience in the biotechnology and medical technology industry as well as five years in investment banking. Dr Chick's previous roles include investment adviser, healthcare analyst for private equity investors, portfolio manager, investment banker and venture capitalist. Dr Chick has advanced a number of technologies from discovery through to market as well as leading capital raisings, M&A transactions, company restructuring, business development and licensing transactions.
Ms Michelle Gallaher	Chief Executive Officer	Mar 2019
Mr Marat Basyrov	Non-Executive Director	Mar 2019	Mr Marat Basyrov Non-Executive Director Mr Basyrov is an experience investor and serial entrepreneur, applying creative and technology-forward data and digital solutions across cross-section of industries. He sits on the board of advisors to Forbes AI. As a Chief Executive Officer of Edway Apps Studio and Intelligent Profit Solutions, Mr Basyrov has a record of building a number of data-driven startup companies including Adevi.io. Mr Basyrov has professional network of directors, investors and collaborators across the globe.
Mr Damon Rasheed	Executive Director	Feb 2019	Mr Damon Rasheed Executive Director Mr Rasheed has experience in the Artificial Intelligence space.

Show All

Director Transactions

Date	Director	Type	Amount	Price	Value	Notes
17/06/21	Marat Basyrov	Transfer	802,000	$0.19	$152,380	Off-market transfer
17/06/21	Marat Basyrov	Transfer	802,000	$0.19	$152,380	Off-market transfer
26/04/21	Julian Chick	Buy	+150,000	$0.15	$22,500	Participation in share purchase plan
26/04/21	Damon Rasheed	Buy	+80,400	$0.15	$12,060	Participation in share purchase plan
18/01/21	Damon Rasheed	Buy	+42,267	$0.165	$6,974	On-market trade
08/09/20	Damon Rasheed	Buy	+30,000	$0.194	$5,820	On-market trade
23/06/20	Julian Chick	Buy	+222,222	$0.09	$19,998	On-market trade
03/12/19	Julian Chick	Buy	+103,274	$0.141	$14,537	On-market trade
15/10/19	Damon Rasheed	Buy	+4,000,000	$0.002	$8,000	On-market trade
14/10/19	Julian Chick	Transfer	4,033,333	$0.002	$8,067	Off-market transfer
14/10/19	Julian Chick	Transfer	4,033,333	$0.002	$8,067	Off-market transfer
14/10/19	Julian Chick	Buy	+9,891,196	$0.002	$19,782	On-market trade
19/07/19	Julian Chick	Issued	1,613,333	$0.001	$1,613	Rights issue
11/01/19	Noah Abelson-Gertler	Expiry	2,916,666	$0.002	$5,833	Options expired
11/01/19	Lee Rodne	Expiry	2,916,666	$0.002	$5,833	Options expired
11/01/19	Noah Abelson-Gertler	Expiry	15,000,000	$0.002	$30,000	As advised by the company

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Marat Basyrov	17/06/2021	0	802,000	129,998	N/A
Megan Robertson	05/05/2021	0	N/A	N/A	N/A
Damon Rasheed	26/04/2021	192,667	N/A	129,998	N/A
Julian Chick	26/04/2021	0	614,741	184,998	N/A
Mark Ziirsen	21/09/2020	0	N/A	N/A	N/A

Show All

Top 20 Shareholders About the Data

Name	Shares	Capital
Scintilla Strategic Investments Limited	1,877,532	5.09%
Altor Capital Management Pty Ltd (Altor Alpha Fund A/C)	1,011,077	2.74%
Hongkong Frank Pty Ltd (Davis Super Fund A/C)	850,000	2.30%
Rewop Pty Ltd (Scott Power Super Fund A/C)	840,669	2.28%
UBS Nominees Pty Ltd	762,500	2.07%
Mr Marat Basyrov	730,000	1.98%
Kamarel Pty Ltd (K F & M L Smith S/F A/C)	700,000	1.90%
Dr Derek Anthony Jellinek	683,153	1.85%
Cs Third Nominees Pty Limited (Hsbc Cust Nom Au Ltd 13 A/C)	619,400	1.68%
Supertank Pty Ltd (Supertank Superfund A/C)	500,000	1.36%
Noah Abelson	491,188	1.33%
Mr Robert Gareth Price & Mr Steven David Price (Simest Super Fund A/C)	406,150	1.10%
DLK Investments Group Pty Ltd (The DLK Investments Unit A/C)	400,000	1.08%
Dr Thomas Peter Clarke & Mrs Gilda Frances Clarke (Tp&Gf Clarke Super Fund A/C)	400,000	1.08%
Mr Elie Chakkour	400,000	1.08%
Mrs Jacinta May Wilkie	399,250	1.08%
Carter Hosking Pty Ltd (Carter Hosking S/Fund A/C)	380,480	1.03%
Doloc Pty Ltd (The Clive Briggs Psl S/F A/C)	361,711	0.98%
Mr Thomas Robert Sartor	360,400	0.98%
RCKC Nominees Pty Ltd	330,000	0.89%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

The most recent Annual Report didn't contain Shareholder Distribution data.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
2020	$0.087	30 June

OPL Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.